JPRN-jRCTs031220192招募中2 期
Safety and pharmacokinetic study of a new PET probe [18F]FEDAC in patients with suspected malignant tumors
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Subjects who are 18 years of age or older at the time of consent acquisition
- •2.Subjects who have been confirmed to have malignant tumors by histopathological examination performed within the past 90 days from the date of consent acquisition or by diagnostic imaging within the past 28 days from the date of consent acquisition
- •3.Subjects whose Performance Status (ECOG PS) is 0 or 1
- •4.Subjects who provide written informed consen
排除标准
- •1.Subjects who have severe or progressive complications or subjects who have a history of these complications and are judged by the investigator or co-investigator to be unsuitable for this study
- •2.Subjects who have obvious abnormalities in physical and laboratory examinations (blood test and urine test) after obtaining the informed consent
- •3.Subjects with drug addiction or alcohol addiction
- •4.Subjects with mental illness or psychiatric symptoms who are judged to have difficulty in participating in this study
- •5.Subjects who are unable or restricted from the tests specified in the research plan
- •6.Subjects who are claustrophobic
- •7.Subjects who is considered to be inappropriate to participate in this study by the investigator or co-investigator
研究者
相似试验
已完成
不适用
First in Human study of a New PET Probe FEDACJPRN-jRCTs031210134Tamura Kentaro10
进行中（未招募）
不适用
A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced AdolescentsEUCTR2008-003917-29-GBGilead Sciences Incorporated24
进行中（未招募）
1 期
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.EUCTR2018-001516-30-BGGUERBET60
进行中（未招募）
1 期
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance ImagingMedDRA version: 22.1Level: LLTClassification code 10029817Term: Nuclear magnetic resonance imaging brainSystem Organ Class: 100000004848MedDRA version: 22.1Level: LLTClassification code 10072232Term: Nuclear magnetic resonance imaging spinalSystem Organ Class: 100000004848EUCTR2018-001516-30-PLGUERBET80
进行中（未招募）
1 期
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.EUCTR2018-001516-30-SKGUERBET80